Terbium-161 labelling of glycoproteins PSMA and monoclonal antibodies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F24%3A00378183" target="_blank" >RIV/68407700:21340/24:00378183 - isvavai.cz</a>

Výsledek na webu

<a href="https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf" target="_blank" >https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Terbium-161 labelling of glycoproteins PSMA and monoclonal antibodies

Popis výsledku v původním jazyce

Terbium-161, as a perspective radionuclide, produced in our institute, was used for labelling of prostate-specific membrane antigen (PSMA) beside the investigation of labelling conditions of selected monoclonal antibodies (MABs) rituximab and bevacizumab. The objective of the first part research task was to prepare radiopharmaceuticals 161Tb-PSMA-617 and 161Tb-PSMA I&T in high abundance and specific activity, to study their stability in biological matrices and in a mouse model. Both radioligands were prepared with yields over 99% and demonstrate sufficient stability in 48 hours post reaction. It was demonstrated high uptake in tumors of both PSMA ligands on LNCaP cell lines in vivo, while 161Tb-PSMA I&T exibit slower clearence and higher retention in lungs and heart. Labelling of MABs was studied on an antibody targeting the vascular endothelial factor (VEGF) angiogenesis-stimulating bevacizumab and the anti-CD20-rituximab targeting conjugate. Both conjugates were prepared by conjugating antibodies with DOTA-NHS. Yields were approximately 20% in both cases. The labeled bevacizumab conjugate was separated from free Tb-161 and applied to a mouse model of the SKOV3 tumor line. After 7 days from the application, most of the antibody was taken up in the tumor tissue. On both models we proved, that Tb-161 produced on LVR-15 meet the criteria for labelling and radioconjugates reveals stability and significant tumor uptake in vivo.

Název v anglickém jazyce

Terbium-161 labelling of glycoproteins PSMA and monoclonal antibodies

Popis výsledku anglicky

Terbium-161, as a perspective radionuclide, produced in our institute, was used for labelling of prostate-specific membrane antigen (PSMA) beside the investigation of labelling conditions of selected monoclonal antibodies (MABs) rituximab and bevacizumab. The objective of the first part research task was to prepare radiopharmaceuticals 161Tb-PSMA-617 and 161Tb-PSMA I&T in high abundance and specific activity, to study their stability in biological matrices and in a mouse model. Both radioligands were prepared with yields over 99% and demonstrate sufficient stability in 48 hours post reaction. It was demonstrated high uptake in tumors of both PSMA ligands on LNCaP cell lines in vivo, while 161Tb-PSMA I&T exibit slower clearence and higher retention in lungs and heart. Labelling of MABs was studied on an antibody targeting the vascular endothelial factor (VEGF) angiogenesis-stimulating bevacizumab and the anti-CD20-rituximab targeting conjugate. Both conjugates were prepared by conjugating antibodies with DOTA-NHS. Yields were approximately 20% in both cases. The labeled bevacizumab conjugate was separated from free Tb-161 and applied to a mouse model of the SKOV3 tumor line. After 7 days from the application, most of the antibody was taken up in the tumor tissue. On both models we proved, that Tb-161 produced on LVR-15 meet the criteria for labelling and radioconjugates reveals stability and significant tumor uptake in vivo.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů